NO134373B - - Google Patents
Download PDFInfo
- Publication number
- NO134373B NO134373B NO2171/71A NO217171A NO134373B NO 134373 B NO134373 B NO 134373B NO 2171/71 A NO2171/71 A NO 2171/71A NO 217171 A NO217171 A NO 217171A NO 134373 B NO134373 B NO 134373B
- Authority
- NO
- Norway
- Prior art keywords
- cyclodextrin
- dissolving
- prostaglandins
- pge2
- solution prepared
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 47
- 150000003180 prostaglandins Chemical class 0.000 claims abstract description 40
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims description 39
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 25
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- -1 substituted Chemical class 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 description 49
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 47
- 239000000047 product Substances 0.000 description 37
- 239000000203 mixture Substances 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 229960002986 dinoprostone Drugs 0.000 description 21
- 238000010438 heat treatment Methods 0.000 description 21
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 21
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 14
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 11
- 239000002775 capsule Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 7
- MYHXHCUNDDAEOZ-UHFFFAOYSA-N Prostaglandin A&2% Natural products CCCCCC(O)C=CC1C=CC(=O)C1CC=CCCCC(O)=O MYHXHCUNDDAEOZ-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000003 vaginal tablet Substances 0.000 description 6
- IMPVDANDCDGWFM-SLESNMHTSA-N (z)-7-[(1r,2r,3r)-3-hydroxy-2-[(e,3s)-3-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid Chemical compound CCCCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O IMPVDANDCDGWFM-SLESNMHTSA-N 0.000 description 5
- 101100310593 Candida albicans (strain SC5314 / ATCC MYA-2876) SOD4 gene Proteins 0.000 description 5
- 101100190148 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PGA2 gene Proteins 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000002220 antihypertensive agent Substances 0.000 description 5
- 239000003433 contraceptive agent Substances 0.000 description 5
- MYHXHCUNDDAEOZ-FOSBLDSVSA-N prostaglandin A2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1C\C=C/CCCC(O)=O MYHXHCUNDDAEOZ-FOSBLDSVSA-N 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 229940124558 contraceptive agent Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- BGKHCLZFGPIKKU-UHFFFAOYSA-N (13E,15S)-15-hydroxy-9-oxo-prosta-10,13-dienoic acid Natural products CCCCCC(O)C=CC1C=CC(=O)C1CCCCCCC(O)=O BGKHCLZFGPIKKU-UHFFFAOYSA-N 0.000 description 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 2
- 239000000924 antiasthmatic agent Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229960004676 antithrombotic agent Drugs 0.000 description 2
- 239000003699 antiulcer agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000001595 contractor effect Effects 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 description 1
- 102100036465 Autoimmune regulator Human genes 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 101000928549 Homo sapiens Autoimmune regulator Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 150000001735 carboxylic acids Chemical group 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- BGKHCLZFGPIKKU-LDDQNKHRSA-N prostaglandin A1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1CCCCCCC(O)=O BGKHCLZFGPIKKU-LDDQNKHRSA-N 0.000 description 1
- 125000003259 prostaglandin group Chemical group 0.000 description 1
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical class CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 229940044977 vaginal tablet Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0025—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing keto groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Nanotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Polymers & Plastics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP45050119A JPS503362B1 (en, 2012) | 1970-06-10 | 1970-06-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO134373B true NO134373B (en, 2012) | 1976-06-21 |
| NO134373C NO134373C (en, 2012) | 1976-09-29 |
Family
ID=12850213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO2171/71A NO134373C (en, 2012) | 1970-06-10 | 1971-06-08 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US3816393A (en, 2012) |
| JP (1) | JPS503362B1 (en, 2012) |
| AT (1) | AT332570B (en, 2012) |
| BE (1) | BE768288A (en, 2012) |
| CA (1) | CA958007A (en, 2012) |
| CH (1) | CH568259A5 (en, 2012) |
| CS (1) | CS170169B2 (en, 2012) |
| CY (1) | CY895A (en, 2012) |
| DE (1) | DE2128674C2 (en, 2012) |
| DK (1) | DK140837B (en, 2012) |
| ES (1) | ES392074A1 (en, 2012) |
| FR (1) | FR2100745B1 (en, 2012) |
| GB (1) | GB1351238A (en, 2012) |
| HK (1) | HK17577A (en, 2012) |
| HU (1) | HU163135B (en, 2012) |
| IE (1) | IE35326B1 (en, 2012) |
| NL (1) | NL162901C (en, 2012) |
| NO (1) | NO134373C (en, 2012) |
| RO (1) | RO62182A (en, 2012) |
| SE (1) | SE390818B (en, 2012) |
| SU (1) | SU404225A3 (en, 2012) |
| ZA (1) | ZA713398B (en, 2012) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4163108A (en) * | 1967-02-16 | 1979-07-31 | Lever Brothers Company | Prostaglandins |
| US4054736A (en) * | 1970-06-10 | 1977-10-18 | Ono Pharmaceutical Co., Ltd. | Clathrate compounds of prostaglandins or their analogues with cyclodextrin |
| US3903131A (en) * | 1971-04-12 | 1975-09-02 | Upjohn Co | 16 and 16,16-dimethyl PGE{HD 2{B |
| CA984387A (en) * | 1971-04-12 | 1976-02-24 | Barney J. Magerlein | Analogs of prostaglandins |
| US3954833A (en) * | 1971-04-12 | 1976-05-04 | The Upjohn Company | 16,16-Methyl and ethyl substituted PGF2.sub.α compounds |
| FR2134673A1 (en) * | 1971-04-30 | 1972-12-08 | Ono Pharmaceutical Co | Novel optically active isomers of prostaglandin analoguesof natural configuration useful as hypotensive agents, diuretics,contraceptives, for treating gastric ulcer and asthma, and forinhibiting platelet aggregation |
| US4045467A (en) * | 1972-02-18 | 1977-08-30 | May & Baker Limited | Cyclopentane derivatives |
| US4082789A (en) * | 1972-03-28 | 1978-04-04 | The University Court Of The University Of Edinburgh | Prostaglandins C2 |
| JPS4926258A (en, 2012) * | 1972-07-06 | 1974-03-08 | ||
| US4141914A (en) * | 1972-07-24 | 1979-02-27 | American Cyanamid Company | Novel 11-deoxy-11-substituted prostaglandins of the E and F series |
| US4130721A (en) * | 1972-07-24 | 1978-12-19 | The Upjohn Company | 11-Deoxy PGE2 compounds |
| US4110368A (en) * | 1972-07-24 | 1978-08-29 | American Cyanamid Company | Hydro substituted prostanoic acids and esters |
| JPS4942648A (en, 2012) * | 1972-08-24 | 1974-04-22 | ||
| US3962312A (en) * | 1972-09-21 | 1976-06-08 | Ono Pharmaceutical Company | 9,11,15-Trihydroxy prost-5-enoic acid analogues |
| US3972917A (en) * | 1972-10-27 | 1976-08-03 | American Home Products Corporation | 11-Deoxy 15-methyl prostaglandin E1 |
| JPS5443570B2 (en, 2012) * | 1972-10-27 | 1979-12-20 | ||
| US4092427A (en) * | 1973-04-16 | 1978-05-30 | American Home Products Corporation | Method of inducing abortion using alkyl derivatives of prostanoic acids |
| JPS5623984B2 (en, 2012) * | 1973-04-19 | 1981-06-03 | ||
| US4059576A (en) * | 1973-08-06 | 1977-11-22 | Hoffmann-La Roche, Inc. | 11-Substituted prostaglandins |
| US4052446A (en) * | 1973-08-06 | 1977-10-04 | Hoffmann-La Roche Inc. | 11,16-substituted prostaglandins |
| US4246426A (en) * | 1973-08-06 | 1981-01-20 | Hoffmann-La Roche Inc. | 11-Substituted prostaglandins |
| US4026927A (en) * | 1973-09-25 | 1977-05-31 | Yamanouchi Pharmaceutical Co., Ltd. | Novel prostaglandin derivatives |
| US4036954A (en) * | 1973-11-02 | 1977-07-19 | Yamanouchi Pharmaceutical Co., Ltd. | Stable prostaglandin E group-containing formulation |
| GB1448268A (en) * | 1973-11-13 | 1976-09-02 | May & Baker Ltd | Cyclopentane derivatives |
| GB1441564A (en) * | 1974-02-07 | 1976-07-07 | Upjohn Co | Prostaglandins |
| US4041066A (en) * | 1974-02-07 | 1977-08-09 | The Upjohn Company | 4,5-Cis-didehydro-PGE1 compounds |
| DE2416193C2 (de) * | 1974-04-03 | 1985-08-14 | Hoechst Ag, 6230 Frankfurt | Prostaglandin-Analoge, Verfahren zu ihrer Herstellung sowie ihre Verwendung als cytoprotektives Mittel |
| US4256651A (en) * | 1974-10-02 | 1981-03-17 | The Upjohn Company | 2a,2b-Dihomo-15-alkyl-PGF1β compounds |
| US3974195A (en) * | 1974-10-02 | 1976-08-10 | The Upjohn Company | 2A,2B-Dihomo-15-alkyl-PGF2.sub.α analogs |
| GB1482010A (en) * | 1974-10-28 | 1977-08-03 | Ono Pharmaceutical Co | Prostaglandin analogues |
| DK142235B (da) * | 1974-12-20 | 1980-09-29 | Yamanouchi Pharma Co Ltd | Analogifremgangsmåde til fremstilling af 20-alkoxy-16-methyl-prostadiensyre-derivater. |
| US4207420A (en) * | 1975-02-24 | 1980-06-10 | The Upjohn Company | 2,2-Difluoro-PGF1 analogs |
| US4209637A (en) * | 1975-02-24 | 1980-06-24 | The Upjohn Company | 2,2-Difluoro-PGF2 analogs |
| US4059701A (en) * | 1975-04-17 | 1977-11-22 | American Home Products Corporation | 15-Substituted prostanoic acids for treating bronchial spasm |
| FR2313019A2 (fr) * | 1975-06-04 | 1976-12-31 | Ono Pharmaceutical Co | Nouveaux analogues de prostaglandines et leur procede de preparation |
| US4086269A (en) * | 1975-07-07 | 1978-04-25 | American Home Products Corporation | 11-Deoxy-15-substituted prostaglandins |
| US4026909A (en) * | 1975-07-14 | 1977-05-31 | The Upjohn Company | Cis-13-PGF2.sub.α analogs |
| US4016184A (en) * | 1975-09-17 | 1977-04-05 | The Upjohn Company | 9-Deoxy-9,10-didehydro-PGD1 compounds |
| US4033989A (en) * | 1975-09-17 | 1977-07-05 | The Upjohn Company | 9-Deoxy-PGF2 Analogs |
| US4013695A (en) * | 1975-10-02 | 1977-03-22 | The Upjohn Company | 4,4,5,5-Tetradehydro-PGE1 analogs |
| US4053500A (en) * | 1975-10-02 | 1977-10-11 | The Upjohn Company | 4,4,5,5-Tetradehydro-ω-aryl-PGF1α analogs |
| US4053502A (en) * | 1975-10-02 | 1977-10-11 | The Upjohn Company | 4,4,5,5-Tetradehydro-ω-aryl-PGE1 analogs |
| US4026919A (en) * | 1975-10-23 | 1977-05-31 | The Upjohn Company | PGD2 Substituted esters |
| US4058665A (en) * | 1975-11-06 | 1977-11-15 | Yamanouchi Pharmaceutical Co., Ltd. | Novel 3,15-dilower alkyl PGE2 derivatives |
| US4212987A (en) * | 1976-09-17 | 1980-07-15 | The Upjohn Company | 2,2-Difluoro-PGE1 analogs |
| US4212986A (en) * | 1976-09-17 | 1980-07-15 | The Upjohn Company | 2,2-Difluoro-PGE2 analogs |
| US4169895A (en) * | 1976-09-28 | 1979-10-02 | Pfizer Inc. | Antisecretory 16,16-dimethyl-17-oxaprostaglandins |
| JPS53136513A (en) * | 1977-05-06 | 1978-11-29 | Ono Pharmaceut Co Ltd | Stabilization of prostaglandin-x-related compounds |
| HU179141B (en, 2012) * | 1977-09-23 | 1982-08-28 | ||
| JPS5577440U (en, 2012) * | 1978-11-25 | 1980-05-28 | ||
| US4244883A (en) * | 1979-09-12 | 1981-01-13 | The Upjohn Company | 2a,2b-Dihomo-15-alkyl-PGF2β compounds |
| ZA831186B (en) * | 1982-03-22 | 1983-11-30 | Upjohn Ltd | Gelled pge2/triacetin solutions |
| DE3504044A1 (de) * | 1985-02-04 | 1986-08-07 | Schering AG, Berlin und Bergkamen, 1000 Berlin | 9-halogenprostaglandin-clathrate und ihre verwendung als arzneimittel |
| DE3608088C2 (de) * | 1986-03-07 | 1995-11-16 | Schering Ag | Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten |
| DE3740838A1 (de) * | 1987-11-27 | 1989-06-08 | Schering Ag | Cyclodextrinclathrate von 5-cyano-prostacyclinderivaten und ihre verwendung als arzneimittel |
| US5221695A (en) * | 1987-12-22 | 1993-06-22 | Glaxo Group Limited | Aqueous formulation containing a piperidinylcyclopentylheptenoic acid derivative and beta-cyclodextrin |
| HU204700B (en) * | 1987-12-22 | 1992-02-28 | Glaxo Group Ltd | Process for producing aqueous compositions comprising piperidinyl cyclopentylheptenoic acid derivatives |
| US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5874418A (en) * | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| DE19828881A1 (de) * | 1998-06-22 | 1999-12-23 | Schering Ag | Oxidationsinhibitor bei Prostan-Derivaten |
| US6287603B1 (en) | 1999-09-16 | 2001-09-11 | Nestec S.A. | Cyclodextrin flavor delivery systems |
| KR20070087078A (ko) | 2001-07-23 | 2007-08-27 | 오노 야꾸힝 고교 가부시키가이샤 | Ｅｐ４ 아고니스트를 유효 성분으로 하는 골량 저하 질환의치료제 |
| EP1563846B1 (en) | 2002-10-10 | 2012-08-29 | Ono Pharmaceutical Co., Ltd. | Endogenous repair factor production promoters |
| JP4666257B2 (ja) | 2003-07-25 | 2011-04-06 | 小野薬品工業株式会社 | 軟骨関連疾患治療剤 |
| CN100542537C (zh) * | 2004-07-27 | 2009-09-23 | 中国人民解放军军事医学科学院毒物药物研究所 | 前列腺素e1口腔制剂 |
| US20090029020A1 (en) * | 2005-06-13 | 2009-01-29 | Cargill, Incorporated | Cyclodextrin inclusion complexes and methods of preparing same |
| KR20080023682A (ko) * | 2005-06-13 | 2008-03-14 | 카아길, 인코포레이팃드 | 시클로덱스트린 포접 착물 및 그의 제조 방법 |
| CA2654799A1 (en) * | 2006-06-13 | 2007-12-21 | Cargill, Incorporated | Large-particle cyclodextrin inclusion complexes and methods of preparing same |
| MX2009007084A (es) * | 2006-12-27 | 2009-08-20 | Cargill Inc | Complejos de inclusion de ciclodextrina y metodos para preparar los mismos. |
| AU2008215431C1 (en) | 2007-02-16 | 2013-10-17 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for urinary excretion disorder |
| RU2009145280A (ru) | 2007-05-08 | 2011-06-20 | Нэшнл Юниверсити Корпорейшн, Хамамацу Юниверсити Скул Оф Медсин (Jp) | Активатор цитотоксических т-клеток, включающий агонист ep4 |
| US20080283693A1 (en) * | 2007-05-15 | 2008-11-20 | Evans Michael J F | Propulsion apparatus and system |
| MX2011013283A (es) | 2009-06-10 | 2012-01-12 | Ono Pharmaceutical Co | Compuesto con actividad de contraccion del musculo detrusor y actividad relajante del musculo esfinter de la uretra. |
| JP4890657B1 (ja) * | 2011-06-03 | 2012-03-07 | 小野薬品工業株式会社 | リマプロストとβ−シクロデキストリンを含有する錠剤 |
| RU2627842C2 (ru) | 2011-08-02 | 2017-08-14 | Оно Фармасьютикал Ко., Лтд. | Средство для улучшения диастолической функции левого желудочка |
| KR102119619B1 (ko) | 2012-08-31 | 2020-06-05 | 오노 야꾸힝 고교 가부시키가이샤 | 아민염과 그 결정 |
| EP3456710B1 (en) | 2016-05-09 | 2021-06-30 | Agc Inc. | Novel prostaglandin derivative |
| WO2023037934A1 (ja) * | 2021-09-13 | 2023-03-16 | 富士フイルム株式会社 | ビシクロアルカン化合物の包摂体の製造方法 |
-
1970
- 1970-06-10 JP JP45050119A patent/JPS503362B1/ja active Pending
-
1971
- 1971-05-26 US US00147255A patent/US3816393A/en not_active Expired - Lifetime
- 1971-05-26 ZA ZA713398A patent/ZA713398B/xx unknown
- 1971-06-03 AT AT480371A patent/AT332570B/de not_active IP Right Cessation
- 1971-06-04 CH CH813871A patent/CH568259A5/xx not_active IP Right Cessation
- 1971-06-07 RO RO67198A patent/RO62182A/ro unknown
- 1971-06-08 NO NO2171/71A patent/NO134373C/no unknown
- 1971-06-09 DE DE2128674A patent/DE2128674C2/de not_active Expired
- 1971-06-09 CY CY895A patent/CY895A/xx unknown
- 1971-06-09 ES ES392074A patent/ES392074A1/es not_active Expired
- 1971-06-09 NL NL7107894.A patent/NL162901C/xx not_active IP Right Cessation
- 1971-06-09 IE IE710/71A patent/IE35326B1/xx unknown
- 1971-06-09 GB GB1978571*[A patent/GB1351238A/en not_active Expired
- 1971-06-09 DK DK279771AA patent/DK140837B/da not_active IP Right Cessation
- 1971-06-09 SU SU1668708A patent/SU404225A3/ru active
- 1971-06-09 SE SE7107486A patent/SE390818B/xx unknown
- 1971-06-09 BE BE768288A patent/BE768288A/xx not_active IP Right Cessation
- 1971-06-10 HU HUOO173A patent/HU163135B/hu not_active IP Right Cessation
- 1971-06-10 CS CS4254A patent/CS170169B2/cs unknown
- 1971-06-10 CA CA115,284A patent/CA958007A/en not_active Expired
- 1971-06-10 FR FR7121129A patent/FR2100745B1/fr not_active Expired
-
1977
- 1977-04-14 HK HK175/77A patent/HK17577A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AT332570B (de) | 1976-10-11 |
| CA958007A (en) | 1974-11-19 |
| DK140837C (en, 2012) | 1981-09-07 |
| IE35326L (en) | 1971-12-10 |
| DK140837B (da) | 1979-11-26 |
| US3816393A (en) | 1974-06-11 |
| RO62182A (en, 2012) | 1977-07-15 |
| ATA480371A (de) | 1976-01-15 |
| CY895A (en) | 1977-10-07 |
| DE2128674C2 (de) | 1982-06-24 |
| FR2100745A1 (en, 2012) | 1972-03-24 |
| FR2100745B1 (en, 2012) | 1974-08-30 |
| SU404225A3 (en, 2012) | 1973-10-26 |
| NL162901B (nl) | 1980-02-15 |
| IE35326B1 (en) | 1976-01-07 |
| SE390818B (sv) | 1977-01-24 |
| BE768288A (fr) | 1971-11-03 |
| DE2128674A1 (de) | 1971-12-16 |
| HK17577A (en) | 1977-04-22 |
| ZA713398B (en) | 1972-01-26 |
| NL7107894A (en, 2012) | 1971-12-14 |
| HU163135B (en, 2012) | 1973-06-28 |
| CS170169B2 (en, 2012) | 1976-08-27 |
| ES392074A1 (es) | 1974-08-01 |
| CH568259A5 (en, 2012) | 1975-10-31 |
| NO134373C (en, 2012) | 1976-09-29 |
| JPS503362B1 (en, 2012) | 1975-02-04 |
| GB1351238A (en) | 1974-04-24 |
| NL162901C (nl) | 1980-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO134373B (en, 2012) | ||
| US4054736A (en) | Clathrate compounds of prostaglandins or their analogues with cyclodextrin | |
| NO173440B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive cyclodextrinclathrater av carbacyclinanaloger | |
| US4479944A (en) | Composition containing PGI2 analogs stabilized | |
| JPS6152146B2 (en, 2012) | ||
| JPH0764808B2 (ja) | 新規９―ハロゲンプロスタグランジン及びその製法 | |
| US5625083A (en) | Dinitroglycerol esters of unsaturated fatty acids and prostaglandins | |
| JPH09501943A (ja) | 新規９−クロル−プロスタグランジン−誘導体 | |
| US5047525A (en) | 9-haloprostaglandin clathrates and their use as medicines | |
| JPH0227970B2 (en, 2012) | ||
| DE3704825A1 (de) | Prostaglandin e1-derivate als pharmazeutische wirkstoffe und diese verbindungen enthaltende arzneimittel insbesondere zur transkutanen anwendung | |
| IE42671B1 (en) | Prostaglandin containing compositions | |
| JPS6054933B2 (ja) | プロスタグランジン及びプロスタグランジン類似化合物製剤の安定化法 | |
| CH677790A5 (en, 2012) | ||
| JPH07157431A (ja) | 安定なプロスタグランジンｅ製剤 | |
| JPH05503713A (ja) | ９―ハロゲン―１１β―ヒドロキシ―プロスタグランジン誘導体、その製造法および医薬品としてのその使用 | |
| JPS584763A (ja) | Δ８，９―プロスタグランジン誘導体及びその製法 | |
| IL33226A (en) | Omega-nor and omega-homo pgf2beta derivatives and process for their preparation | |
| Matsumuraa et al. | Synthesis and biological properties of novel fluoroprostaglandin derivatives: Highly selective and potent agonists for prostaglandin receptors | |
| CN101617827B (zh) | 一种异甜菊醇或其衍生物的超分子组合物及其制备方法 | |
| JPS5819675B2 (ja) | １９ ２０− ビス−ノル−プロスタンサンノ セイホウ | |
| WO1991013634A1 (de) | 9-chlor-prostaglandin-beta-cyclodextrin-clathrate und ihre verwendung als arzneimittel | |
| JPH02167227A (ja) | イソカルバサイクリン誘導体を活性成分として含有する糖尿病性神経症治療剤 | |
| JPS6130551A (ja) | ４−ビフエニリル酢酸−シクロデキストリン包接化合物 | |
| BE821696A (fr) | Procede de preparation d'une formulation stable contenant une prostaglandine du groupe e |